M&A Deal Summary |
|
|---|---|
| Date | 2020-07-21 |
| Target | LEO PDE4 Inhibitor |
| Sector | Life Science |
| Buyer(s) | UNION therapeutics A/S |
| Sellers(s) | LEO Pharma |
| Deal Type | Divestiture |
| Deal Value | 200M USD |
SEARCH BY
Try For Free 7-Day Free Trial
UNION therapeutics A/S is a privately held, clinical-stage pharmaceutical company dedicated to the development of novel treatments for inflammatory and infectious diseases. The company is working on two complementary chemistry classes spanning immunology and microbiology and has three candidates in clinical development. UNION is headquartered in Hellerup (Denmark) and managed by an experienced team across Europe and the USA.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (Denmark) | 1 of 1 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1908 |
| Sector | Life Science |
| Employees | 4,285 |
| Revenue | 1.4B EUR (2022) |
LEO Pharma engages in medical dermatology with a robust R&D pipeline, a wide range of therapies, and a pioneering spirit. LEO Pharma supports people in managing their skin conditions. LEO Pharma was founded in 1908 and is based in Ballerup, Denmark.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (Denmark) | 1 of 1 |
| Year (2020) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-11 |
Astellas Pharma - Global Dermatology
United States Astellas Pharma - Global Dermatology is a provider of pharmaceutical services. |
Buy | €675M |
